David Livingston

David serves as President and Chief Scientific Officer of MetroBiotech, a company developing therapeutics for treatment of diseases of aging and mitochondrial disorders. Prior to joining Metro, David held positions as Senior Vice President, Biology at Ensemble Therapeutics, a macrocycle chemistry company, President and CEO of Spherics, Inc., a drug delivery company, and President/CEO at Praelux Inc. (acquired by GE Healthcare), which invented a rapid confocal imaging platform for high-content cell assay-based drug discovery. Before leading Praelux, David was Vice President and Program Executive at Vertex Pharmaceuticals where he managed therapeutic programs in inflammation, immunology, and virology. David earned his PhD from the University of California at Davis and an MBA from Northeastern University in Boston. After his PhD, he pursued postdoctoral studies in enzymology (at M.I.T.) and in protein engineering (at The Johns Hopkins Medical School). David is an inventor on more than 40 granted US patents and has co-authored more than 60 peer-reviewed publications, and he is a visiting lecturer in Brown University’s Division of Biology and Medicine, where he teaches graduate students about drug discovery and the biology of aging.